Novartis acquires U.K. cancer biotech Myricx Bio for $1.5 billion
Novartis agreed to acquire Myricx Bio, a privately held U.K. biotechnology company, for up to $1.5 billion, adding…
Novartis Acquires Pikavation for Up to $3B, Expanding Cancer Pipeline
Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics…
Novartis, UNP, Launch Up-to-$1.8B+ Macrocyclic Peptide Partnership
Novartis will apply Unnatural Products (UNP)’s artificial intelligence (AI)-guided macrocyclic peptide platform to develop next-generation cardiovascular disease therapeutics,…